
SNWV Stock Forecast & Price Target
SNWV Analyst Ratings
Bulls say
SANUWAVE Health Inc. demonstrated significant financial growth in the fiscal year 2024, with a notable 60% year-over-year increase in sales, reaching a total of $32.6 million. Additionally, the company achieved an increase in Adjusted EBITDA (AEBITDA) of 28 percentage points, bringing it to 22%, indicating improved operational efficiency and profitability. While operating expenses did rise due to non-cash stock-based compensation and NASDAQ fees, the overall financial trajectory signals a strong position for SANUWAVE in the regenerative medicine market.
Bears say
The financial outlook for SANUWAVE Health appears negative due to a decline in applicator usage during the first quarter, which is typically influenced by seasonal factors such as patients postponing treatments following the reset of annual insurance deductibles. Additionally, the company faces several challenges, including margin compression, competitive pressures, and reduced sales representative productivity, which could hinder future growth. Furthermore, manufacturing setbacks could further impede operational effectiveness and sales performance, creating additional concerns for investors.
This aggregate rating is based on analysts' research of SANUWAVE Health Inc and is not a guaranteed prediction by Public.com or investment advice.
SNWV Analyst Forecast & Price Prediction
Start investing in SNWV
Order type
Buy in
Order amount
Est. shares
0 shares